Regulatory panel unconvinced by Alzheimer’s antibody evidence
By 
Anthony King2020-11-20T09:29:00
US FDA advisors vote against approving Biogen’s aducanumab on the basis of incomplete data analysis
Biogen’s evidence surrounding the effectiveness of its experimental Alzheimer’s antibody, aducanumab, has been roundly criticised by a panel of independent experts advising the US Food and Drug Administration (FDA). The company had submitted the treatment for regulatory approval after a controversial re-analysis of halted clinical trials suggested it might be effective at slowing cognitive decline at high doses.